Get the Stockscreener App
0.8723
12.33%
-0.1227
After Hours:
.87
-0.0023
-0.26%
Celularity Inc stock is traded at $0.8723, with a volume of 34,201.
It is down -12.33% in the last 24 hours and down -8.46% over the past month.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
See More
Previous Close:
$0.995
Open:
$1.02
24h Volume:
34,201
Relative Volume:
0.17
Market Cap:
$25.25M
Revenue:
$26.55M
Net Income/Loss:
$-91.72M
P/E Ratio:
-0.2434
EPS:
-3.584
Net Cash Flow:
$-13.25M
1W Performance:
-13.63%
1M Performance:
-8.46%
6M Performance:
-55.94%
1Y Performance:
-54.57%
1-Day Range:
$0.85
$1.02
1-Week Range:
$0.85
$1.075
52-Week Range:
$0.7101
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
0.8723 | 28.80M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - The Manila Times
New Florida law lets doctors use placental cell therapy before FDA approval - Stock Titan
Celularity names Rick Gonzalez as chief commercial officer - Investing.com UK
Celularity: Actions Are Intended to Streamline Business and Concentrate Resources >CELU - Moomoo
Celularity refocuses on cell therapy after biomaterials sale - Investing.com
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - TipRanks
Celularity names Rick Gonzalez as Chief Commercial Officer - TradingView
New Celularity (NASDAQ: CELU) CCO to drive cenplacel-L and Lifebank growth - Stock Titan
Celularity Releases CEO Letter to Shareholders - The Manila Times
Celularity outlines placenta cell therapy push to extend health span - Stock Titan
Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer - geneonline.com
Celularity names Rick Gonzalez as chief commercial officer By Investing.com - Investing.com Canada
New Celularity commercial chief to expand Lifebank cell banking - Stock Titan
Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer, Effective May 29, 2026 - marketscreener.com
Celularity Receives Nasdaq Notice Regarding Form 10-Q - marketscreener.com
Celularity face Nasdaq listing rule breach after missing Q1 10-Q SEC filing - MSN
Celularity gets Nasdaq notice for delayed Q1 2026 Form 10-Q filing, must submit compliance plan by July 28. - Pluang
Celularity Inc. Notified of Non-Compliance with Nasdaq Listing Rule Due to Delayed 10-Q Filing - Quiver Quantitative
Nasdaq flags Celularity for missing Q1 2026 10-Q filing - Stock Titan
Celularity Enters Settlement, Restructuring Financing Obligations - TipRanks
Celularityenters settlement agreement with Helena on May 21, 2026 - marketscreener.com
Celularity Settles With Helena; $500,000 Upfront, 5x$100,000 Payments and $2.5M Note Rights - TradingView
Celularity (NASDAQ: CELU) restructures Helena preferred stock deal with cash and note rights - Stock Titan
Celularity Inc. (CELU) Surges 8% to $0.99 as Stock Tests Key ResistanceEarly Entry Signals - thelegaladvocate.com
Celularity (CELU) Edges Higher: Navigating Key Resistance at $0.97PCR Divergence - thelegaladvocate.com
CELU - Finviz
Why Is Celularity Inc. (GXGX) Stock Up Today? - Meyka
Why Is Celularity Inc. (GXGXW) Stock Down Today? - Meyka
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (NASDAQ: CELU) notifies SEC of delayed Q1 2026 10-Q - Stock Titan
NexGel Q1 2026 Earnings Call Transcript - MarketBeat
TradingKey - TradingKey
Sequence execs join NEXGEL (NASDAQ: NXGL) board after $5.5M note deal - Stock Titan
Is Celularity (CELU) a value trap or a value play? (Recovers) 2026-05-08Certified Trade Ideas - Newser
The hidden strength in Celularity (CELU) most investors miss (Underperforming) 2026-05-07Viral Trades - Newser
Celularity regains Nasdaq compliance after delayed filing - MSN
After $5.5M deal backing, Sequence executives take 2 NEXGEL board seats - Stock Titan
NEXGEL Appoints Brian Kieser and Kevin Harris from New - GlobeNewswire
NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal - MyChesCo
Celularity Inc. 2025 Annual 10-K Report: Financials, Debt, Equity, and Major Agreements Overview - Minichart
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - Investing News Network
Stocks to watch on Friday after hours: CTLP, CELU, ULH (CTLP:NASDAQ) - Seeking Alpha
Celularity Regains Nasdaq Listing Compliance, Shares Rise - marketscreener.com
Celularity regains Nasdaq compliance after filing annual report By Investing.com - Investing.com Australia
Celularity regains Nasdaq compliance after filing annual report - Investing.com
Nasdaq closes Celularity listing case after delayed 10-K filing - Stock Titan
CELU SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Celularity : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) - marketscreener.com
[10-K] Celularity Inc Files Annual Report - Stock Titan
NEXGEL (NASDAQ: NXGL) hires new CFO to support Celularity deal - Stock Titan
Celularity Inc FY 2025: Revenue $26.6M, EPS $(3.59) — 10-K Summary - TradingView
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celularity Inc Stock (CELU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haines John R | Senior Exec Vice President |
Apr 13 '26 |
Option Exercise |
0.00 |
1,641 |
0 |
30,762 |
| Hariri Robert J | Chief Executive Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
3,281 |
0 |
2,854,735 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):